Galderma Group N - Asset Resilience Ratio

Latest as of June 2025: 3.56%

Galderma Group N (GALD) has an Asset Resilience Ratio of 3.56% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check GALD strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets

CHF458.00 Million

≈ $579.04 Million USD Cash + Short-term Investments

Total Assets

CHF12.88 Billion

≈ $16.28 Billion USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2021–2024)

This chart shows how Galderma Group N's Asset Resilience Ratio has changed over time. See GALD equity financing ratio to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Galderma Group N's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Galderma Group N.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CHF458.00 Million	3.56%
Short-term Investments	CHF0.00	0%
Total Liquid Assets	CHF458.00 Million	3.56%

Asset Resilience Insights

Limited Liquidity: Galderma Group N maintains only 3.56% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Galderma Group N Industry Peers by Asset Resilience Ratio

Compare Galderma Group N's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Swedish Orphan Biovitrum AB (publ) ST:SOBI	Drug Manufacturers - Specialty & Generic	1.54%
Aurobindo Pharma Limited NSE:AUROPHARMA	Drug Manufacturers - Specialty & Generic	1.28%
Shijiazhuang Yiling Pharmaceutical Co Ltd SHE:002603	Drug Manufacturers - Specialty & Generic	11.60%
Shandong Buchang Pharmaceuticals Co Ltd SHG:603858	Drug Manufacturers - Specialty & Generic	3.47%
Tianjin Chase Sun Pharmaceutical Co Ltd SHE:300026	Drug Manufacturers - Specialty & Generic	-0.89%
Zhejiang Hisoar Pharmaceutical Co Ltd SHE:002099	Drug Manufacturers - Specialty & Generic	0.20%
Xeris Pharmaceuticals Inc NASDAQ:XERS	Drug Manufacturers - Specialty & Generic	0.00%
Procter & Gamble Health Limited NSE:PGHL	Drug Manufacturers - Specialty & Generic	33.01%

Annual Asset Resilience Ratio for Galderma Group N (2021–2024)

The table below shows the annual Asset Resilience Ratio data for Galderma Group N.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	2.64%	CHF333.59 Million ≈ $421.75 Million	CHF12.62 Billion ≈ $15.95 Billion	+0.41pp
2023-12-31	2.23%	CHF234.26 Million ≈ $296.17 Million	CHF10.49 Billion ≈ $13.26 Billion	+2.23pp
2022-12-31	0.00%	CHF185.04K ≈ $233.94K	CHF11.49 Billion ≈ $14.52 Billion	-0.02pp
2021-12-31	0.02%	CHF2.46 Million ≈ $3.11 Million	CHF11.45 Billion ≈ $14.48 Billion	--

pp = percentage points

About Galderma Group N

SW:GALD Switzerland Drug Manufacturers - Specialty & Generic

Market Cap

$50.84 Billion

CHF40.21 Billion CHF

Market Cap Rank

#739 Global

#11 in Switzerland

Share Price

CHF171.25

Change (1 day)

-0.98%

52-Week Range

CHF110.70 - CHF172.95

All Time High

CHF172.95